RxDoctor Payments Data

Ronald Gim, MD

Cardiovascular Disease · Laguna Hills, CANPI 1316039753

Payments from drug & device makers

$17,306in general payments, 2019–2025

Across 694 payments — averaging $24.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$3K
  • Novartis$1K
  • Boston Scientific$1K
  • Amgen$824
  • Inari Medical, Inc.$813
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$813
  • plus $10K from 48 others

What the payments were for

  • Travel & lodging$7915%
  • Food & beverage$16,35495%
  • Education$1611%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,306 in reported general payments places this provider in the 80th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$525,533
Medicare patients
865
Services billed
4,762

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban240$267,729
XareltoRivaroxaban205$224,151
EntrestoSacubitril/Valsartan113$129,943
Repatha SureclickEvolocumab68$63,722
MultaqDronedarone Hcl20$20,142
BrilintaTicagrelor31$17,551
Praluent PenAlirocumab21$14,411
EdarbyclorAzilsartan Med/Chlorthalidone34$13,994
NexlizetBempedoic Acid/Ezetimibe14$8,710
JardianceEmpagliflozin12$5,509
Diltiazem 12hr ErDiltiazem Hcl13$4,264
VascepaIcosapent Ethyl12$4,090
Rosuvastatin Calcium262$3,838
Flecainide Acetate87$3,631
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide103$3,411

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$362$267,729240 claims
Johnson & JohnsonXarelto$316$224,151205 claims
NovartisEntresto$1,409$129,943113 claims
Sanofi-aventis U.S. LLCMultaq$460$20,14220 claims
AstraZenecaBrilinta$23$17,55131 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$60$13,99434 claims
Esperion Therapeutics, Inc.Nexlizet$205$8,71014 claims
Boehringer IngelheimJardiance$521$5,50912 claims
ANI Pharmaceuticals, Inc.Valsartan$24$1,93397 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Laguna Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →